Gold prices bounce off 3-week lows; demand likely longer term
Burlington (NYSE:BURL), NC—Labcorp Holdings Inc. (NYSE:LH), a prominent healthcare services provider with a market capitalization of $19.23 billion and an "GOOD" financial health rating according to InvestingPro, recently reported transactions by its Executive Vice President and Chief Marketing Officer, Amy Summy, involving the company’s common stock. According to the SEC filing, Summy sold 758 shares on March 28, 2025, at a price of $231.67 per share, totaling approximately $175,605. This sale was conducted under a pre-established trading plan in accordance with Rule 10b5-1. The transaction price was near the middle of Labcorp’s 52-week range of $191.97 to $258.59, with analysts maintaining a consensus buy rating and a high target of $300 per share.
In a separate transaction on March 27, 2025, Summy acquired 2,077 shares without any cash exchange, as part of a performance award granted in February 2022, which was based on the company’s performance over a three-year period ending December 31, 2024. Additionally, 562 shares were withheld at the same price of $231.67 per share to cover tax obligations, amounting to $130,198.
Following these transactions, Summy’s direct ownership stands at 5,301.5 shares.
In other recent news, Laboratory Corporation of America, known as LabCorp, announced an agreement to acquire oncology-focused laboratory testing assets from BioReference Health for $192.5 million, with potential additional payments of up to $32.5 million. This acquisition is expected to contribute immediately to LabCorp’s earnings, generating approximately $85 million to $100 million in annual revenue. Truist Securities has maintained a Buy rating on LabCorp, with a price target of $285, citing the company’s strong financial position and strategic acquisitions as positive factors. Additionally, Citi analysts upgraded LabCorp’s stock rating from Neutral to Buy, raising the price target to $300, driven by strong utilization rates in the labs industry and the company’s strategic acquisitions.
LabCorp has also introduced Labcorp Plasma Complete, a liquid biopsy test for advanced cancer care, enhancing its oncology portfolio by offering comprehensive genomic profiling. This test, validated in LabCorp’s CAP-accredited and CLIA-certified laboratory, provides oncologists with actionable insights for personalized treatment plans. The company’s ongoing mergers and acquisitions strategy, including a recent purchase of clinical testing and reproductive health assets from BioReference, supports its goal of achieving 1.5% to 2.5% annual revenue growth. These strategic moves, along with robust cash flow and financial flexibility, are expected to support continued investments in LabCorp’s core business trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.